SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) March 29, 1996
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification no.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
<PAGE>
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On March 29, 1996, Biocontrol Technology, Inc.
announced that it recently withdrew a Securities and
Exchange Commission (SEC) preregistration of 5,000,000
shares of stock because recent events made it
impossible for the Company to abide by the SEC's "quiet
period" mandated while registration is pending. This
quiet period prohibits a company from advertising or
promoting in any fashion. At the time the
preregistration was submitted, the Company could not
have foreseen the publicity that would occur and cause
a need for extensive communication with its
stockholders regarding its Diasensor 1000 noninvasive
glucose sensor for diabetics and the status of the
Company.
Biocontrol also stated that such registration can
be submitted to the SEC in the future if necessary,
after a period of time.
The Company stressed that, in the meantime, it has
other means of raising capital; i.e., private
placement, selling to institutions, investments from
corporate partners, etc.
At this time, Biocontrol has sufficient cash to
carry it through any additional testing required by the
FDA. To fund an initial startup inventory for the
Diasensor 1000 noninvasive glucose sensor, it will be
necessary for the Company to sell additional shares.
The withdrawal of the SEC preregistration in no
way effects the special shareholders' meeting scheduled
for 9:00 a.m., April 11, 1996, at the Westin William
Penn Hotel in Pittsburgh, PA. At that meeting, besides
being updated on the Company's various projects, the
stockholders have been asked to authorize an additional
20,000,000 shares of stock.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired
Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - News Release
<PAGE>
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: March 29, 1996
